Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a report released on Friday morning.

Protalix BioTherapeutics Stock Down 2.8 %

Protalix BioTherapeutics stock opened at $2.46 on Friday. Protalix BioTherapeutics has a twelve month low of $0.82 and a twelve month high of $2.54. The business has a fifty day moving average of $1.91 and a two-hundred day moving average of $1.37. The firm has a market cap of $181.13 million, a P/E ratio of -18.92 and a beta of 0.71.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PLX. PFG Investments LLC purchased a new stake in shares of Protalix BioTherapeutics during the 4th quarter valued at $39,000. Sanctuary Advisors LLC acquired a new stake in Protalix BioTherapeutics in the third quarter worth about $38,000. Virtu Financial LLC purchased a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at approximately $44,000. XTX Topco Ltd acquired a new stake in Protalix BioTherapeutics in the 3rd quarter worth approximately $36,000. Finally, GSA Capital Partners LLP grew its position in Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after purchasing an additional 33,969 shares during the last quarter. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.